FDA Approves Second Dose of CAR T-Cell Therapy in Ovarian Cancer Trial

The FDA has approved an individual patient IND, allowing for a second dose of a novel FSHR-targeting CAR T-cell therapy for the treatment of a patient with recurrent ovarian cancer that may be demonstrating clinical activity to the initial treatment.